Browse AMR Genes
Explore antimicrobial resistance genes from the literature
Explore antimicrobial resistance genes from the literature
thymidylate synthase A
Overview
| Protein Change | Nucleotide Change | Mechanism | Organism | Resistance To | Database | Validation Status |
|---|---|---|---|---|---|---|
| C161T | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acid | Card Database | Established |
| T202A | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPyrazinamide | Card DatabaseReslit | Confirmed | |
| - |
| - |
| Escherichia coli |
Trimethoprim-sulfamethoxazole |
Reslit |
| Candidate |
| T22A | - | single resistance variant | Mycobacterium tuberculosis | PASPara-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder DatabaseReslit | Confirmed |
| H75N | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder DatabaseReslit | Confirmed |
| S105P | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder Database | Confirmed |
| F152V | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder Database | Confirmed |
| G76Ter | - | nonsense mutation | Mycobacterium tuberculosis | Para-aminosalicylic acid | Card Database | Established |
| H207R | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder Database | Confirmed |
| V77F | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder Database | Confirmed |
| W101R | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder Database | Confirmed |
| R126Q | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder Database | Confirmed |
| W83Ter | - | nonsense mutation | Mycobacterium tuberculosis | Para-aminosalicylic acid | Card Database | Established |
| P224L | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder Database | Confirmed |
| Y36C | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder Database | Confirmed |
| W98Ter | - | nonsense mutation | Mycobacterium tuberculosis | Para-aminosalicylic acid | Card Database | Established |
| R235P | single resistance variant, loss of function | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder DatabaseReslit | Confirmed |
| G91R | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder Database | Confirmed |
| W83C | - | single resistance variant | Mycobacterium tuberculosis | Para-aminosalicylic acidPara-aminosalicyclic acid | Card DatabaseResFinder Database | Confirmed |
| W83* | - | - | Mycobacterium tuberculosis | Para-aminosalicyclic acid | ResFinder Database | Established |
| C161Y | - | - | Mycobacterium tuberculosis | Para-aminosalicyclic acid | ResFinder Database | Established |
| R222G | - | - | Mycobacterium tuberculosis | Para-aminosalicyclic acid | ResFinder Database | Established |
| W98* | - | - | Mycobacterium tuberculosis | Para-aminosalicyclic acid | ResFinder Database | Established |
| G76* | - | - | Mycobacterium tuberculosis | Para-aminosalicyclic acid | ResFinder Database | Established |
| A114V | - | - | - | Para-aminosalicylic acid | Reslit | Candidate |
| Q10P | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| W80* | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| F176L | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| Q111X | - | - | - | Para-aminosalicylic acid | Reslit | Candidate |
| T26P | - | - | - | Para-aminosalicylic acid | Reslit | Candidate |
| S125F | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| Y94C | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| V135F | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| Q97R | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| T51A | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| D305G | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| L2Q | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| P303R | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| P303G | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| F231Y | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| Q124K | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| N92K | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| L2W | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| T51M | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| L214Q | - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| V261G | - | The mutation leads to changes in the dUMP and MTHF binding sites, weak interaction of ThyA enzyme with dUMP and MTHF, loss of hydrogen bond and other atomic interactions, and enhanced movement of protein atoms. | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| L172P | - | The mutation leads to changes in the dUMP and MTHF binding sites, weak interaction of ThyA enzyme with dUMP and MTHF, loss of hydrogen bond and other atomic interactions, and enhanced movement of protein atoms. | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| R127L | - | The mutation leads to changes in the dUMP and MTHF binding sites, weak interaction of ThyA enzyme with dUMP and MTHF, loss of hydrogen bond and other atomic interactions, and enhanced movement of protein atoms. | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| L143P | - | The mutation leads to changes in the dUMP and MTHF binding sites, weak interaction of ThyA enzyme with dUMP and MTHF, loss of hydrogen bond and other atomic interactions, and enhanced movement of protein atoms. | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| C146R | - | The mutation leads to changes in the dUMP and MTHF binding sites, weak interaction of ThyA enzyme with dUMP and MTHF, loss of hydrogen bond and other atomic interactions, and enhanced movement of protein atoms. | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| A182P | - | The mutation leads to changes in the dUMP and MTHF binding sites, weak interaction of ThyA enzyme with dUMP and MTHF, loss of hydrogen bond and other atomic interactions, and enhanced movement of protein atoms. | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| A113G | - | - | Mycobacterium tuberculosis | Trimethoprim | Reslit | Candidate |
| D20Y | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| E137G | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| 264fs | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| 39fs | - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | Mycobacterium tuberculosis | Para-aminosalicyclic acid | ResFinder Database | Established |
| - | - | Mycobacterium tuberculosis | Para-aminosalicyclic acid | ResFinder Database | Established |
| - | - | Mycobacterium tuberculosis | Para-aminosalicyclic acid | ResFinder Database | Established |
| - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| - | - | Mycobacterium tuberculosis | Para-aminosalicylic acid | Reslit | Candidate |
| - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | Mycobacterium tuberculosis | Para-aminosalicyclic acid | ResFinder Database | Established |
| - | - | Mycobacterium tuberculosis | Para-aminosalicyclic acid | ResFinder Database | Established |
| - | - | Staphylococcus aureus | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
| - | - | - | Trimethoprim-sulfamethoxazole | Reslit | Candidate |
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
The study identifies mutations in the thyA gene as a cause of para-aminosalicylic acid (PAS) resistance in Mycobacterium tuberculosis, with 37% of PAS-resistant isolates having such mutations.
Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid.
Deletion of thyA in Mycobacterium tuberculosis confers resistance to p-aminosalicylic acid (PAS). Functional analysis shows that the T202A mutation in thyA restores PAS sensitivity, whereas the V261G mutation does not.
Increase in Furfural Tolerance in Ethanologenic Escherichia coli LY180 by Plasmid-Based Expression of thyA.
The study shows that plasmid-based expression of the thyA gene from Bacillus subtilis, Escherichia coli, and Zymomonas mobilis enhances furfural tolerance in ethanologenic E. coli LY180. This improvement is attributed to increased dTMP availability for DNA repair.
dfrA thyA Double Deletion in para-Aminosalicylic Acid-Resistant Mycobacterium tuberculosis Beijing Strains.
Deletions in dfrA and thyA contribute to para-aminosalicylic acid resistance in Mycobacterium tuberculosis Beijing strains.
Inactivation of the Thymidylate Synthase thyA in Non-typeable Haemophilus influenzae Modulates Antibiotic Resistance and Has a Strong Impact on Its Interplay with the Host Airways.
Inactivation of the thyA gene in non-typeable Haemophilus influenzae increases resistance to cotrimoxazole (TxS) and affects bacterial physiology and host interactions.
Machine learning and structural analysis of Mycobacterium tuberculosis pan-genome identifies genetic signatures of antibiotic resistance.
The study identifies 33 known AMR genes and 24 new genetic signatures of AMR in Mycobacterium tuberculosis using machine learning and structural analysis. It also reveals 97 epistatic interactions across 10 resistance classes and provides mechanistic insights into the selection of these genes.
Evolutionary Coupling of Folate Metabolic Enzymes Reveals Adaptive Units in Bacterial Adaptation
The study identifies DHFR and TYMS as an adaptive unit in folate metabolism, showing that mutations in these genes can confer resistance to trimethoprim through balanced metabolite concentration regulation.
A biochemically-interpretable machine learning classifier for microbial GWAS.
The study identifies pncA, ppsA, ansP2, thyA, cysK2, and katG as key genetic determinants of pyrazinamide, para-aminosalicylic acid, and isoniazid resistance in Mycobacterium tuberculosis using a metabolic allele classifier (MAC).
Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis.
The study identifies several genes and mutations associated with drug resistance in Mycobacterium tuberculosis, including katG, inhA, rpoB, embB, pncA, rpsL, rrs, gyrA, thyA, and folC, which are linked to resistance against isoniazid, ethambutol, rifampicin, streptomycin, aminoglycosides, fluoroquinolones, and para-aminosalicylic acid.
Intragenic Distribution of IS6110 in Clinical Mycobacterium tuberculosis Strains: Bioinformatic Evidence for Gene Disruption Leading to Underdiagnosed Antibiotic Resistance.
The study identifies IS6110-mediated gene disruptions in clinical Mycobacterium tuberculosis strains that lead to resistance against bedaquiline, clofazimine, ethionamide, pyrazinamide, and para-aminosalicylic acid.
Adaptation of S. aureus towards persistence in cystic fibrosis using WGS
The paper discusses the genetic adaptation of Staphylococcus aureus in cystic fibrosis patients, highlighting the role of horizontal gene transfer, mutations, and regulatory mechanisms in the development of persistent infections and resistance. It emphasizes the importance of whole genome sequencing in understanding the population dynamics and evolution of S. aureus in the CF airways.
CGA-LMM identifies expected interactions for anti-tubercular drugs with known mechanisms
The study identifies genes involved in resistance to anti-tubercular drugs through chemical-genetic interaction analysis, highlighting gyrA, rpoB, thyA, ino1, and kasB as key players in resistance mechanisms for fluoroquinolones, rifampin, sulfamethoxazole, and isoniazid.
Phenotypic and genotypic characterisation of thymine auxotrophy in Escherichia coli isolated from a patient with recurrent bloodstream infection.
The study identifies a G172C mutation in the thyA gene, leading to thymine auxotrophy and resistance to TMP-SMX in E. coli isolates from a patient with recurrent bloodstream infections.
Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.
The study identifies thyA, folC, and dfrA mutations as the primary mechanisms of para-aminosalicylic acid (PAS) resistance in Mycobacterium tuberculosis. It establishes 4 μg/ml as the critical concentration for distinguishing PAS-susceptible and resistant isolates.
Genomic analysis of Mycobacterium tuberculosis variant bovis strains isolated from bovine in the state of Mato Grosso, Brazil.
The study identified multiple AMR genes and mutations in Mycobacterium tuberculosis variant bovis strains from Mato Grosso, Brazil, including resistance to pyrazinamide, isoniazid, rifampicin, streptomycin, ethambutol, ethionamide, fluoroquinolones, kanamycin, capreomycin, paraminosalicylic acid, cycloserine, bedaquiline, linezolid, and delamanid.
Comparative genome analysis reveals high-level drug resistance markers in a clinical isolate of Mycobacterium fortuitum subsp. fortuitum MF GZ001.
The study identifies multiple drug resistance markers in the clinical isolate of Mycobacterium fortuitum subsp. fortuitum MF GZ001, including mutations in genes such as rpoB, katG, AAC(2')-Ib, gyrA, gyrB, embB, pncA, thyA, embC, embR, and iniA, which confer resistance to various antibiotics.
Whole genome sequencing reveals candidate genes involving in PAS resistance in M. Tuberculosis isolated from patients in Thailand.
The study identified mutations in thyA, thyX, folC, and ribD genes, along with intergenic regions, that contribute to PAS resistance in M. tuberculosis. These mutations were validated through complementation assays and MIC testing.
Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coli.
The study reveals that E. coli develops resistance to antibiotics faster than to antimicrobial peptides (AMPs). Trimethoprim-resistant E. coli with mutations in the thyA gene shows increased susceptibility to pexiganan.
No comments yet. Be the first to comment!
© 2026 ResLit. Data sourced from PubMed literature analysis.
Built for antimicrobial resistance research